PBE

Weekly Report: what happened at PBE last week (0415-0419)?

Equity Market Outlook Q2 2024: Extreme Distortions Everywhere - A Moment For Active Management

Home Market Outlook Today's Equity Market Outlook Q2 2024: Extreme Distortions Everywhere - A Moment For Active Management. Neuberger Berman: U.S. Economic growth has remained resilient and leads the world. Global Industrial Activity Is Picking Up While Early Signs Of Moderating Growth in Europe. We believe extreme market consensus presents a moment for active management.

Weekly Report: what happened at PBE last week (0408-0412)?

Weekly Report: what happened at PBE last week (0401-0405)?

PBE: Biotech Could Be Next Big Winner

Invesco Biotechnology & Genome ETF offers comprehensive exposure to the biotech sector with a diversified portfolio. Biotechnology and genomics sector has not performed well in recent years. PBE has performed better than some similar ETFs but worse than others. The fund is diversified across 32 US biotechnology and genome companies.

Weekly Report: what happened at PBE last week (0325-0329)?

Weekly Report: what happened at PBE last week (0318-0322)?

ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons

ARK Genomic Revolution ETF warrants a hold rating due to underdeveloped technology, legal hurdles, and unresolved ethical dilemmas. The fund's performance has significantly underperformed the S&P 500 Index. ARKG has a relatively high expense ratio with no dividend yield and is concentrated in the healthcare sector.